UBS Asset Management Americas Inc. Holds Stake in Novavax, Inc. (NASDAQ:NVAX)
UBS Asset Management Americas Inc. maintained its position in Novavax, Inc. (NASDAQ:NVAX) during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 83,106 shares of the biopharmaceutical company’s stock at the end of the first quarter. UBS Asset Management Americas Inc.’s holdings in Novavax were worth $106,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Norges Bank bought a new position in Novavax during the fourth quarter valued at approximately $3,300,000. Renaissance Technologies LLC bought a new position in Novavax during the fourth quarter valued at approximately $544,000. Canada Pension Plan Investment Board bought a new position in Novavax during the first quarter valued at approximately $157,000. Teachers Advisors LLC raised its position in Novavax by 4.2% in the fourth quarter. Teachers Advisors LLC now owns 455,686 shares of the biopharmaceutical company’s stock valued at $574,000 after buying an additional 18,519 shares during the period. Finally, Bank of New York Mellon Corp raised its position in Novavax by 0.9% in the first quarter. Bank of New York Mellon Corp now owns 1,215,100 shares of the biopharmaceutical company’s stock valued at $1,555,000 after buying an additional 10,347 shares during the period. 50.16% of the stock is owned by institutional investors.
Novavax, Inc. (NASDAQ:NVAX) opened at 1.01 on Monday. The company has a 50-day moving average price of $1.17 and a 200-day moving average price of $1.17. The company’s market capitalization is $285.42 million. Novavax, Inc. has a one year low of $0.73 and a one year high of $8.49.
Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. The company had revenue of $5.68 million during the quarter, compared to analyst estimates of $6.17 million. Novavax had a negative net margin of 1,466.36% and a negative return on equity of 787.38%. The company’s revenue was up 34.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.29) earnings per share. Equities research analysts anticipate that Novavax, Inc. will post ($0.61) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/07/ubs-asset-management-americas-inc-holds-stake-in-novavax-inc-nasdaqnvax.html.
NVAX has been the subject of several recent research reports. ValuEngine lowered Novavax from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Cantor Fitzgerald set a $2.00 target price on Novavax and gave the company a “hold” rating in a report on Monday, May 8th. BidaskClub lowered Novavax from a “hold” rating to a “sell” rating in a report on Wednesday, July 19th. Zacks Investment Research lowered Novavax from a “buy” rating to a “hold” rating in a report on Wednesday, July 26th. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and set a $1.50 target price on shares of Novavax in a report on Wednesday, July 26th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Novavax has an average rating of “Hold” and an average price target of $5.61.
In other news, insider Stanley C. Erck acquired 50,000 shares of the company’s stock in a transaction dated Thursday, May 11th. The stock was bought at an average price of $0.84 per share, with a total value of $42,000.00. Following the completion of the acquisition, the insider now owns 128,279 shares in the company, valued at approximately $107,754.36. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders have bought 107,057 shares of company stock valued at $92,631. Company insiders own 4.00% of the company’s stock.
Novavax Company Profile
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Want to see what other hedge funds are holding NVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novavax, Inc. (NASDAQ:NVAX).
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.